Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tivozanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 20/20 | 0.90 |
| ▸ | FLT1 known ✓ | P17948 | 4/20 | 0.90 |
| ▸ | FLT4 known ✓ | P35916 | 4/20 | 0.90 |
| ▸ | KIT known ✓ | P10721 | 3/20 | 0.90 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.90 |
| ▸ | PDGFRA | P16234 | 12/20 | 0.90 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.90 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.90 |
| ▸ | STK10 | O94804 | 2/20 | 0.90 |
| ▸ | ABL1 | P00519 | 2/20 | 0.90 |
| ▸ | RET | P07949 | 2/20 | 0.90 |
| ▸ | BCR | P11274 | 2/20 | 0.90 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.90 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.90 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.90 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.90 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.90 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.90 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.90 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tivozanib SCHEMBL172883 | 0.95 | KDR (1.00) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL29354604 | 0.95 | KDR (1.00) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL29354238 | 0.95 | KDR (1.00) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL1869882 | 0.94 | KDR (0.98) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL30993908 | 0.94 | KDR (0.98) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL21174286 | 0.93 | KDR (0.97) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL29394095 | 0.93 | KDR (0.97) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL5209537 | 0.92 | KDR (0.93) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL5214691 | 0.92 | KDR (0.93) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL5211590 | 0.90 | KDR (0.90) | KDRPDGFRAFLT1FLT4KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559715-B1 | N-{2-CHLORO-4-[(6,7-DIMETHOXY-4-QUINOLYL)OXY]PHENYL}-N'-(5-METHYL-3-ISOXAZOLYL)UREA SALT IN CRYSTALLINE FORM | KIRIN BREWERY (JP) | 2007-09-26 | — | — | EP | disclosed |
| US-7166722-B2 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20060052415-A1 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-03-09 | — | — | US | disclosed |
| EP-1559715-A1 | N-[2-CHLORO-4-(6,7-DIMETHOXY-4-QUINOLYL)OXY]PHENYL]-N'-(5-METHYL-3-ISOXAZOLYL)UREA SALT IN CRYSTALLINE FORM | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052415-A1 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form | UACA, REN, TPMT | KDR 421/4885FLT1 1068/4885FLT4 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.